1
|
Scheemaeker S, Peremans K, Vandermeulen E, Duchateau L, Roggeman T, Daminet S. Effect of recombinant human thyroid stimulating hormone on radioactive iodine uptake by thyroid carcinoma in dogs. J Vet Intern Med 2024; 38:2273-2281. [PMID: 39023205 PMCID: PMC11256155 DOI: 10.1111/jvim.17132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Accepted: 05/31/2024] [Indexed: 07/20/2024] Open
Abstract
BACKGROUND The high doses of radioiodine-131 (131I) and, subsequently, the high radioactive burden for dog and environment warrants optimization of 131I therapy in dogs with thyroid carcinoma (TC). HYPOTHESIS/OBJECTIVES To evaluate the effect of a revised protocol with recombinant human thyroid stimulating hormone (rhTSH) on tumor radioactive iodine uptake (RAIU) in dogs with TC. ANIMALS Nine client-owned dogs diagnosed with TC. METHODS A prospective cross-over study in which tumor RAIU was calculated and compared at 8 hours (8h-RAIU) and 24 hours (24h-RAIU) after injection of radioactive iodine-123 (123I), once with and once without rhTSH (ie, 250 μg, IM, 24 and 12 hours before 123I) in each dog. Simultaneously, serum total thyroxine (TT4) and TSH were measured at baseline (T0), and 6 (T6), 12 (T12), 24 (T24), and 48 hours (T48) after the first rhTSH administration. RESULTS Tumor RAIU was significantly higher at 24 hours with rhTSH compared to no rhTSH (mean difference = 8.85%, 95% CI of [1.56; 16.14]; P = .03), while this was non-significant at 8 hours (mean difference = 4.54%, 95% CI of [0.35; 8.73]; P = .05). A significant change of serum TT4 (median difference T24 - T0 = 35.86 nmol/L, interquartile range [IQR] = 15.74 nmol/L) and TSH (median difference T24 - T0 = 1.20 ng/mL, IQR = 1.55 ng/mL) concentrations occurred after administration of rhTSH (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE Recombinant human TSH could optimize 131I treatment in dogs with TC by increasing tumor RAIU and thus 131I treatment efficacy.
Collapse
Affiliation(s)
- Stephanie Scheemaeker
- Small Animal Department, Faculty of Veterinary MedicineGhent University, Salisburylaan 1339820 MerelbekeBelgium
| | - Kathelijne Peremans
- Department of Morphology, Imaging, Orthopedics, Rehabilitation and Nutrition, Faculty of Veterinary MedicineGhent University, Salisburylaan 1339820 MerelbekeBelgium
| | - Eva Vandermeulen
- Department of Morphology, Imaging, Orthopedics, Rehabilitation and Nutrition, Faculty of Veterinary MedicineGhent University, Salisburylaan 1339820 MerelbekeBelgium
| | - Luc Duchateau
- Department of Morphology, Imaging, Orthopedics, Rehabilitation and Nutrition, Faculty of Veterinary MedicineGhent University, Salisburylaan 1339820 MerelbekeBelgium
| | - Tom Roggeman
- Small Animal Department, Faculty of Veterinary MedicineGhent University, Salisburylaan 1339820 MerelbekeBelgium
| | - Sylvie Daminet
- Small Animal Department, Faculty of Veterinary MedicineGhent University, Salisburylaan 1339820 MerelbekeBelgium
| |
Collapse
|
2
|
Maurin MP, Davies D, Jahns H, Shiel RE, Mooney CT. Non-functional thyroid cystadenoma in three boxer dogs. BMC Vet Res 2019; 15:228. [PMID: 31277644 PMCID: PMC6612076 DOI: 10.1186/s12917-019-1948-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Accepted: 06/04/2019] [Indexed: 11/18/2022] Open
Abstract
Background Thyroid neoplasia is a common endocrine neoplasm in dogs. The boxer is one of the reported breeds predisposed to malignant thyroid neoplasia. However, the association between thyroid neoplasia, malignancy and breed should be considered with caution. Cases presentation This article describes the presentation, clinical pathological findings, computed tomographic (CT) imaging findings and histopathological features of benign cystic thyroid tumour (cystadenoma) diagnosed in three boxers. These three dogs were presented for investigation of unilateral (n = 2) or bilateral (n = 1) cervical masses with no associated clinical signs of thyroid dysfunction. In each case, post-contrast CT scan identified a large, lateralised, non-invasive, well-defined homogeneous cystic structure with a hyperattenuating contrast-enhancing capsule of suspected thyroid origin displacing the surrounding cervical tissues. Ultrasound-guided fine needle aspiration of the cysts yielded fluid with a high thyroxine concentration in each case. Histopathology was consistent with thyroid cystadenoma in all cases. One dog was concurrently diagnosed with oral melanoma and euthanased. Two dogs underwent surgical excision with one lost to follow-up after 36 months and the other euthanased after 16 months following diagnosis of mast cell tumour. Conclusions To the authors’ knowledge, this is the first detailed report of non-functional benign thyroid cystadenoma in dogs and provides relevant information about case management for this type of tumour. The presence of a large cystic structure associated with benign non-functional thyroid neoplasia may be a condition to which boxer dogs are predisposed.
Collapse
Affiliation(s)
| | - Dan Davies
- School of Veterinary Medicine, University College Dublin, Dublin, Ireland
| | - Hanne Jahns
- School of Veterinary Medicine, University College Dublin, Dublin, Ireland
| | - Robert E Shiel
- School of Veterinary Medicine, University College Dublin, Dublin, Ireland
| | - Carmel T Mooney
- School of Veterinary Medicine, University College Dublin, Dublin, Ireland
| |
Collapse
|
3
|
Pessina P, Castillo V, Sartore I, Borrego J, Meikle A. Semiquantitative immunohistochemical marker staining and localization in canine thyroid carcinoma and normal thyroid gland. Vet Comp Oncol 2014; 14:e102-12. [DOI: 10.1111/vco.12111] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Accepted: 06/22/2014] [Indexed: 12/27/2022]
Affiliation(s)
- P. Pessina
- Laboratorio de Técnicas Nucleares; Facultad de Veterinaria; Montevideo Uruguay
| | - V. Castillo
- Cátedra Clínica Médica Pequeños Animales, U. Endocrinología, Htal. Escuela de Medicina Veterinaria, Facultad de Ciencias Veterinarias; Universidad de Buenos Aires; Buenos Aires Argentina
| | - I. Sartore
- Laboratorio de Técnicas Nucleares; Facultad de Veterinaria; Montevideo Uruguay
| | - J. Borrego
- Instituto Veterinario de Oncología Comparada (IVOC); Valencia Spain
- Hospital Veterinario Facultad de Veterinaria y Ciencias Experimentales; Universidad Católica de Valencia “San Vicente Martir”; Valencia Spain
| | - A. Meikle
- Laboratorio de Técnicas Nucleares; Facultad de Veterinaria; Montevideo Uruguay
| |
Collapse
|
4
|
Deitz K, Gilmour L, Wilke V, Riedesel E. Computed tomographic appearance of canine thyroid tumours. J Small Anim Pract 2014; 55:323-9. [DOI: 10.1111/jsap.12219] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/19/2014] [Indexed: 12/28/2022]
Affiliation(s)
- K. Deitz
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine; Iowa State University; Ames IA 50011 USA
| | - L. Gilmour
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine; Iowa State University; Ames IA 50011 USA
| | - V. Wilke
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine; University of Minnesota; St. Paul MN 55108 USA
| | - E. Riedesel
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine; Iowa State University; Ames IA 50011 USA
| |
Collapse
|
5
|
Campos M, Peremans K, Vandermeulen E, Duchateau L, Bosmans T, Polis I, Daminet S. Effect of recombinant human thyrotropin on the uptake of radioactive iodine (¹²³I) in dogs with thyroid tumors. PLoS One 2012; 7:e50344. [PMID: 23209716 PMCID: PMC3510219 DOI: 10.1371/journal.pone.0050344] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2012] [Accepted: 10/18/2012] [Indexed: 11/18/2022] Open
Abstract
In humans, recombinant human thyrotropin (rhTSH) enhances radioactive iodine uptake (RAIU) in patients with differentiated thyroid cancer. No studies have been performed in veterinary medicine to optimize radioiodine treatment of thyroid cancer. The aim of this study was to evaluate the effect of rhTSH on the uptake of radioiodine-123 ((123)I) in dogs with thyroid tumors. Nine dogs with thyroid neoplasia were included in this prospective cross-over study. The dogs were divided in 2 groups. In one group, (123)I was administered for a baseline RAIU determination in week 1. In week 2 (after a washout period of 2 weeks), these dogs received rhTSH (100 μg IV) 24 h before (123)I injection. In the other group the order of the protocol was reversed. For each scan, the dogs received 37 MBq (1 mCi) of (123)I intravenously (IV) and planar scintigraphy was performed after 8 and 24 h for tumor RAIU calculation. Overall, rhTSH administration caused no statistically significant change on thyroid tumor RAIU at 8 h (p = 0.89) or at 24 h (p = 0.98). A significant positive correlation was found between the effect of rhTSH on tumor 8h-RAIU and rhTSH serum concentrations at 6 h (τ = 0.68; p = 0.03), at 12 h (τ = 0.68; p = 0.03) and at 24 h (τ = 0.78; p = 0.02) after rhTSH injection. This study suggests that IV administration of 100 μg rhTSH 24 h before (123)I has an inconsistent effect on thyroid tumor RAIU. Further studies are necessary to determine the best protocol of rhTSH administration to optimize thyroid tumor RAIU.
Collapse
Affiliation(s)
- Miguel Campos
- Department of Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
| | | | | | | | | | | | | |
Collapse
|
6
|
Expression of thyroid-specific transcription factors in thyroid carcinoma, contralateral thyroid lobe and healthy thyroid gland in dogs. Res Vet Sci 2012; 93:108-13. [DOI: 10.1016/j.rvsc.2011.06.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2011] [Revised: 05/20/2011] [Accepted: 06/02/2011] [Indexed: 01/26/2023]
|
7
|
Campos M, van Hoek I, Peremans K, Daminet S. Recombinant human thyrotropin in veterinary medicine: current use and future perspectives. J Vet Intern Med 2012; 26:853-62. [PMID: 22676297 DOI: 10.1111/j.1939-1676.2012.00950.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2011] [Revised: 04/03/2012] [Accepted: 04/21/2012] [Indexed: 11/29/2022] Open
Abstract
Recombinant human thyrotropin (rhTSH) was developed after bovine thyrotropin (bTSH) was no longer commercially available. It was approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) as an aid to diagnostic follow-up of differentiated thyroid carcinoma in humans and for thyroid remnant ablation with radioiodine. In addition, rhTSH is used in human medicine to evaluate thyroid reserve capacity and to enhance radioiodine uptake in patients with metastatic thyroid cancer and multinodular goiter. Likewise, rhTSH has been used in veterinary medicine over the last decade. The most important veterinary use of rhTSH is thyroidal functional reserve testing for the diagnosis of canine hypothyroidism. Recent pilot studies performed at Ghent University in Belgium have investigated the use of rhTSH to optimize radioiodine treatment of canine thyroid carcinoma and feline hyperthyroidism. Radioiodine treatment optimization may allow a decreased therapeutic dosage of radioiodine and thus may improve radioprotection. This review outlines the current uses of rhTSH in human and veterinary medicine, emphasizing research performed in dogs and cats, as well as potential future applications.
Collapse
Affiliation(s)
- M Campos
- Department of Medicine and Clinical Biology of Small Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
| | | | | | | |
Collapse
|
8
|
Abstract
The clinical presentation and biologic behavior of thyroid tumors vary widely among dogs, cats, and human beings. Although thyroid tumors in dogs are rare, they are most likely to be malignant. Clinical signs are usually the result of impingement on surrounding structures, and clinical hyperthyroidism is rare. In contrast, hyperthyroidism resulting from benign thyroid proliferation is relatively common among older cats. Malignant tumors are extremely uncommon but have high metastatic potential. Irrespective of the tumor's ability to produce functional thyroid hormone, scintigraphy is often helpful in the diagnosis and staging of thyroid tumors in all three species. Treatment with surgery is a reasonable treatment option for noninvasive tumors. Iodine 131 is a well-established treatment for thyroid nodules in cats, but its effectiveness in dogs is controversial. In dogs, external beam radiation therapy has produced more consistent results in affording local tumor control when surgery is not possible.
Collapse
Affiliation(s)
- Lisa G Barber
- Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, 200 Westboro Road, North Grafton, MA 01536, USA.
| |
Collapse
|
9
|
Rijnberk A, Kooistra HS, Mol JA. Endocrine diseases in dogs and cats: similarities and differences with endocrine diseases in humans. Growth Horm IGF Res 2003; 13 Suppl A:S158-S164. [PMID: 12914747 DOI: 10.1016/s1096-6374(03)00076-5] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Over several millennia, humans have created hundreds of dog and cat breeds by selective breeding, including fixation of mutant genes. The domestic dog is unique in the extent of its variation in height, weight and shape as well as its behavior. It is primarily the relatively long persistence of high levels of growth hormone (GH) release at a young age that accounts for the large body size in giant breeds of dogs. Several of the endocrine diseases of humans are also known to occur as similar entities in dogs and cats. With some variations, this is true for conditions such as diabetes mellitus and the hypofunction syndromes of the thyroid and adrenal cortex. Also, the hyperfunction syndromes of hypercortisolism and hyperparathyroidism in dogs and cats have many similarities with their human counterparts. The exception seems to be Graves' disease. This condition, which is due to production of thyroid-stimulating hormone (TSH)-receptor antibodies, has not been observed in dogs and cats. The very common form of hyperthyroidism in cats is due to toxic adenomas. In the 1980s it was discovered that in dogs exogenous progestins and endogenous progesterone can induce GH excess. This GH excess originates form the mammary gland and may give rise to acromegaly and insulin resistance. GH production by the mammary gland is not unique to the dog. It has become clear that cats and humans also express the GH gene in the mammary gland. There is increasing evidence that this locally produced GH not only plays a role in the morphologic changes of the mammary gland associated with the ovarian cycle and gestation, but that it is also involved in the development of breast cancer. In dogs, induction of mammary GH production by progestin administration allows for treatment of GH deficiency.
Collapse
Affiliation(s)
- Ad Rijnberk
- Department of Clinical Sciences of Companion Animals, Utrecht University, P.O. Box 80.154, 3508, TD Utrecht, The Netherlands.
| | | | | |
Collapse
|
10
|
Abstract
Because of the diverse nature of endocrine organs, and their vast range of physiologic functions, endocrine tumors encompass a wide range of origination sites and disease entities. The clinical picture of affected individuals is highly dependent on the tissue of origin, and the presence or absence of functional hormone secretions. Identification, localization, and therapeutic strategies, as well as prognosis can vary greatly. Many endocrine tumors have been described in human as well as veterinary patients. This article focuses on endocrine tumors of dogs and cats. Various tumors affecting the pancreas, thyroid, parathyroid, adrenal and pituitary glands are described, including insulinoma, gastrinoma, glucagonoma, and thyroid carcinoma, as well as parathyroid hormone- and growth hormone-secreting tumors. The syndrome of multiple endocrine neoplasia is also described.
Collapse
Affiliation(s)
- J C Lurye
- Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA.
| | | |
Collapse
|
11
|
Tanaka K, Sonoo H, Yamamoto Y, Udagawa K, Kunisue H, Arime I, Yamamoto S, Kurebayashi J, Shimozuma K. Changes of expression level of the differentiation markers in papillary thyroid carcinoma under thyrotropin suppression therapy in vivo immunohistochemical detection of thyroglobulin, thyroid peroxidase, and thyrotropin receptor. J Surg Oncol 2000; 75:108-16. [PMID: 11064390 DOI: 10.1002/1096-9098(200010)75:2<108::aid-jso7>3.0.co;2-v] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND AND OBJECTIVES Differences in the expression levels of Thyroglobulin (Tg), Thyroid peroxidase (TPO) and thyrotropin receptor (TSH-R) in primary and recurrent specimens under a suppressive serum TSH condition were elucidated in 26 papillary carcinoma patients. METHODS Immunohistochemical detection was performed by use of each monoclonal antibody against Tg, TPO, and TSH-R. The staining concentrations of the three markers in each specimen were measured for comparison. RESULTS The mean staining concentrations of Tg, TPO, and TSH-R in the entire primary tumor were 103.92, 104.6 and 89.25, respectively. Five cases showed stronger expression of all the differentiation markers and eight cases showed weaker expression of all these markers in recurrent tissue than in primary tumors. The weaker expression of TSH-R at the recurrent site as compared with that at the primary site significantly demonstrated the shortness of the disease free interval or overall survival. There were significant differences between the death due to cancer and the weaker expression of TSH-R in the recurrent tumor as compared with that in the primary tumor. CONCLUSIONS Under the TSH suppressive condition, the markers were not expressed uniformly among recurrent tumors. Even under that state, however, low expression of TSH-R in the recurrent tissue was strongly related to a poorer outcome in the patients.
Collapse
Affiliation(s)
- K Tanaka
- Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Tanaka K, Inoue H, Miki H, Masuda E, Kitaichi M, Komaki K, Uyama T, Monden Y. Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma: immunohistochemical detection of TSH-R. Br J Cancer 1997; 76:594-9. [PMID: 9303357 PMCID: PMC2228017 DOI: 10.1038/bjc.1997.431] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
We have demonstrated the expression of thyrotropin receptor (TSH-R) in thyroid neoplasms (13 adenomas, 21 papillary carcinomas, two follicular carcinomas) and adjacent normal thyroid using the monoclonal antibody against human TSH-R and have also demonstrated a relationship between prognostic scores and the expression of TSH-R. Among the adenomas, eight showed an intensity similar to that of normal thyroid and five showed a higher intensity than normal. Two tumours exhibited heterogeneous distribution of TSH-R. Among the papillary carcinomas, seven showed similar intensity to normal tissue and four showed higher intensity and ten showed weaker intensity. Eight tumours showed heterogeneous distribution of the stain. Among the follicular carcinomas, one showed similar intensity to normal tissue and the other exhibited weaker intensity. Both cases showed homogeneous distribution of TSH-R. The adenomas never showed a weaker intensity than normal thyroid, but various intensities of TSH-R occurred in differentiated carcinomas. There was no significant relationship between the clinical data and the signal intensity in the adenomas. Among the papillary carcinomas, however, the group with weaker intensity had significantly poorer prognostic scores than the other two groups. Thus, we assume that low TSH-R may be expressed by the clinically high-risk group of patients with papillary thyroid carcinoma.
Collapse
Affiliation(s)
- K Tanaka
- The Second Department of Surgery, School of Medicine, The University of Tokushima, Japan
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Happ GM. Thyroiditis--a model canine autoimmune disease. ADVANCES IN VETERINARY SCIENCE AND COMPARATIVE MEDICINE 1995; 39:97-139. [PMID: 8578979 DOI: 10.1016/s0065-3519(06)80018-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- G M Happ
- Department of Biology, University of Vermont, Burlington 05405, USA
| |
Collapse
|